Rockefeller Capital Management L.P. Has $5.61 Million Holdings in CRISPR Therapeutics AG $CRSP

Rockefeller Capital Management L.P. increased its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 27.5% during the second quarter, Holdings Channel reports. The fund owned 115,356 shares of the company’s stock after purchasing an additional 24,853 shares during the period. Rockefeller Capital Management L.P.’s holdings in CRISPR Therapeutics were worth $5,611,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. IFP Advisors Inc boosted its stake in CRISPR Therapeutics by 24.6% in the second quarter. IFP Advisors Inc now owns 916 shares of the company’s stock worth $45,000 after purchasing an additional 181 shares in the last quarter. Teacher Retirement System of Texas raised its stake in shares of CRISPR Therapeutics by 1.1% in the second quarter. Teacher Retirement System of Texas now owns 22,066 shares of the company’s stock worth $1,073,000 after acquiring an additional 243 shares during the last quarter. SFE Investment Counsel raised its stake in shares of CRISPR Therapeutics by 5.8% in the first quarter. SFE Investment Counsel now owns 6,507 shares of the company’s stock worth $221,000 after acquiring an additional 355 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of CRISPR Therapeutics by 6.4% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,091 shares of the company’s stock worth $296,000 after purchasing an additional 366 shares in the last quarter. Finally, Ipswich Investment Management Co. Inc. grew its stake in shares of CRISPR Therapeutics by 1.7% during the second quarter. Ipswich Investment Management Co. Inc. now owns 24,968 shares of the company’s stock valued at $1,214,000 after purchasing an additional 425 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

Insider Buying and Selling at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 50,895 shares of the company’s stock in a transaction on Friday, October 17th. The shares were sold at an average price of $67.91, for a total value of $3,456,279.45. Following the completion of the sale, the chief executive officer owned 254,201 shares in the company, valued at $17,262,789.91. This represents a 16.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, General Counsel James R. Kasinger sold 1,076 shares of the firm’s stock in a transaction on Tuesday, October 14th. The stock was sold at an average price of $66.60, for a total value of $71,661.60. Following the sale, the general counsel directly owned 83,402 shares in the company, valued at $5,554,573.20. The trade was a 1.27% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 56,213 shares of company stock valued at $3,810,458 in the last three months. 4.30% of the stock is owned by company insiders.

CRISPR Therapeutics Price Performance

Shares of CRSP stock opened at $49.29 on Friday. The stock has a market cap of $4.70 billion, a PE ratio of -8.82 and a beta of 1.89. The stock has a 50-day moving average of $62.80 and a 200-day moving average of $53.92. CRISPR Therapeutics AG has a one year low of $30.04 and a one year high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, November 10th. The company reported ($1.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.15. CRISPR Therapeutics had a negative net margin of 1,273.70% and a negative return on equity of 21.23%. The firm had revenue of $0.89 million during the quarter, compared to analysts’ expectations of $8.74 million. As a group, research analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Wall Street Analyst Weigh In

CRSP has been the subject of several research analyst reports. Barclays boosted their price objective on shares of CRISPR Therapeutics from $42.00 to $56.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. Zacks Research raised CRISPR Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. Chardan Capital reiterated a “buy” rating and issued a $82.00 price target on shares of CRISPR Therapeutics in a report on Tuesday, August 5th. Royal Bank Of Canada boosted their price objective on CRISPR Therapeutics from $42.00 to $50.00 and gave the stock a “sector perform” rating in a report on Tuesday, November 11th. Finally, JPMorgan Chase & Co. initiated coverage on shares of CRISPR Therapeutics in a research note on Thursday, September 18th. They issued an “overweight” rating and a $70.00 target price on the stock. Eleven research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $67.84.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.